Filing Flows › Companies › Aktis Oncology › Cash flow
Aktis Oncology cash flow, quarter by quarter
Latest: Q2 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$21.8M in Q2 2026
Analysis
In Q2 2026, Aktis Oncology generated −$20.6M of operating cash flow and spent $1.3M on capital projects, leaving free cash flow of −$21.8M. That is $4.1M less than in Q2 2025 (−$17.7M).
Operating cash flow was −$20.6M against net income of −$24.1M. The largest differences: deferred revenue −$3.4M, stock-based pay +$3.2M, prepaid and other assets −$1.6M.
Free cash flow
Where the cash came from and went
From profit to cash
Every quarter
| Quarter | Operating cash flow | Capital spending | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|---|
| Q2 2026 | −$20.6M | −$1.3M | $156K | $289M | −$21.8M |
| Q1 2026 | −$24.2M | −$1.9M | $5.4M | −$334M | −$26.1M |
| Q2 2025 | −$16.2M | −$1.5M | — | −$52.0M | −$17.7M |
| Q1 2025 | −$17.5M | −$1.9M | $50K | −$21.1M | −$19.4M |
Aktis Oncology: income statement and cash flow
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%. The chart follows the revenue to costs, profit and cash.
Aktis Oncology: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.